Loading clinical trials...
Loading clinical trials...
The herbal medicine Qurs-e-Fishar to treat mild to moderate High blood pressure or hypertension comprises of Rauwolfia serpentina. A product of Hamdard Laboratories (Waqf) Pakistan. A Phase III Safety \& Efficacy Open-label, Single-Arm, Interventional, Multicenter, Study in mild to moderate hypertensive, adults (30 to 60 years of age) prescribed with study product for 12 weeks (84 days). Primary End Points: 1. Reduction in diastolic blood pressure less than 130 / 80 mmHg at the end of the study period (accepted by WHO) or if there was a fall of 20 / 10 mmHg or more in diastolic blood pressure as compared to baseline. 2. Type, frequency and severity of ADRs during the study period. Secondary End Points: 1\. Compliance of the prescribed study medication.
Age
30 - 60 years
Sex
ALL
Healthy Volunteers
No
Taj Medical Complex, Hamdard University Hospital
Karachi, Sindh, Pakistan
Start Date
December 23, 2023
Primary Completion Date
June 30, 2025
Completion Date
December 31, 2025
Last Updated
February 28, 2025
119
ESTIMATED participants
Qurs e Fishar
OTHER
Lead Sponsor
Abdul Bari
Collaborators
NCT02417740
NCT07073820
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07480265